Abbott Laboratories (NYSE:ABT) is Hemenway Trust Co LLC's 9th Largest Position

Hemenway Trust Co LLC grew its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 2.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 357,413 shares of the healthcare product maker's stock after purchasing an additional 7,807 shares during the quarter. Abbott Laboratories makes up approximately 3.3% of Hemenway Trust Co LLC's investment portfolio, making the stock its 9th largest position. Hemenway Trust Co LLC's holdings in Abbott Laboratories were worth $40,427,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in ABT. Cape Investment Advisory Inc. lifted its stake in shares of Abbott Laboratories by 6.6% in the 4th quarter. Cape Investment Advisory Inc. now owns 1,236 shares of the healthcare product maker's stock valued at $140,000 after purchasing an additional 76 shares during the last quarter. Cyrus J. Lawrence LLC lifted its position in Abbott Laboratories by 9.0% in the fourth quarter. Cyrus J. Lawrence LLC now owns 954 shares of the healthcare product maker's stock worth $107,000 after buying an additional 79 shares during the last quarter. Jacobson & Schmitt Advisors LLC increased its position in Abbott Laboratories by 2.9% during the fourth quarter. Jacobson & Schmitt Advisors LLC now owns 2,827 shares of the healthcare product maker's stock valued at $320,000 after acquiring an additional 80 shares during the last quarter. LMG Wealth Partners LLC lifted its holdings in shares of Abbott Laboratories by 3.8% in the 4th quarter. LMG Wealth Partners LLC now owns 2,161 shares of the healthcare product maker's stock worth $244,000 after acquiring an additional 80 shares during the last quarter. Finally, Glass Wealth Management Co LLC boosted its stake in shares of Abbott Laboratories by 3.2% during the 4th quarter. Glass Wealth Management Co LLC now owns 2,640 shares of the healthcare product maker's stock worth $299,000 after purchasing an additional 81 shares during the period. 75.18% of the stock is currently owned by institutional investors.

Remove Ads

Insider Activity

In other Abbott Laboratories news, EVP Lisa D. Earnhardt sold 91,167 shares of the business's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $133.82, for a total transaction of $12,199,967.94. Following the completion of the transaction, the executive vice president now owns 71,928 shares in the company, valued at approximately $9,625,404.96. The trade was a 55.90 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of Abbott Laboratories stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $128.50, for a total value of $3,054,573.50. Following the transaction, the executive vice president now owns 125,697 shares in the company, valued at approximately $16,152,064.50. This trade represents a 15.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 116,449 shares of company stock worth $15,463,316. 0.46% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have issued reports on ABT. Citigroup raised their price objective on shares of Abbott Laboratories from $135.00 to $160.00 and gave the stock a "buy" rating in a research note on Tuesday, March 4th. The Goldman Sachs Group lifted their target price on Abbott Laboratories from $138.00 to $154.00 and gave the stock a "buy" rating in a research report on Tuesday, March 4th. Argus upgraded shares of Abbott Laboratories to a "strong-buy" rating in a report on Tuesday, January 28th. UBS Group lifted their price objective on shares of Abbott Laboratories from $146.00 to $148.00 and gave the company a "buy" rating in a report on Thursday, January 23rd. Finally, Wells Fargo & Company upped their target price on shares of Abbott Laboratories from $133.00 to $136.00 and gave the stock an "overweight" rating in a research note on Thursday, January 23rd. Four research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $137.94.

Abbott Laboratories Trading Down 1.6 %

Abbott Laboratories stock traded down $2.04 during trading on Thursday, reaching $125.00. The company had a trading volume of 3,634,840 shares, compared to its average volume of 5,955,669. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. The firm has a market capitalization of $216.79 billion, a price-to-earnings ratio of 16.28, a PEG ratio of 2.52 and a beta of 0.80. Abbott Laboratories has a 12-month low of $99.71 and a 12-month high of $141.23. The stock's 50 day moving average price is $130.88 and its two-hundred day moving average price is $121.17.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Wednesday, January 22nd. The healthcare product maker reported $1.34 EPS for the quarter, hitting analysts' consensus estimates of $1.34. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The business had revenue of $10.97 billion during the quarter, compared to the consensus estimate of $11.03 billion. During the same period in the prior year, the firm posted $1.19 EPS. The business's revenue for the quarter was up 7.2% on a year-over-year basis. As a group, equities analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be paid a $0.59 dividend. The ex-dividend date is Tuesday, April 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.89%. Abbott Laboratories's dividend payout ratio (DPR) is presently 30.85%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.